Edwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve Franchise

1 week ago 5

Soumya Eswaran

Mon, May 11, 2026 astatine 8:13 AM CDT 3 min read

Artisan Partners, an concern absorption company, released its first-quarter 2026 capitalist missive for the “Artisan Mid Cap Fund”. A transcript of the missive is disposable to download here. In Q1 2026, the Artisan Mid Cap Fund reported antagonistic implicit returns but somewhat outperformed the Russell Midcap® Growth Index. The marketplace favored little volatility and income-oriented equities, with worth outpacing maturation significantly. Despite challenges for maturation strategies, selective banal choices successful sectors similar industrials and healthcare provided strength, portion user discretionary faced weaknesses. Mid- and small-cap indices showed resilience amid lagging large-cap maturation stocks. The escalating struggle successful Iran influenced marketplace behavior, and AI-related investments continued to enactment superior spending and earnings. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, Artisan Mid Cap Fund highlighted stocks similar Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) is simply a starring aesculapian exertion institution specializing successful the attraction of precocious cardiovascular diseases. On May 8, 2026, Edwards Lifesciences Corporation (NYSE:EW) closed astatine $79.96 per share. One-month instrumentality of Edwards Lifesciences Corporation (NYSE:EW) was 2.36%, and its shares gained 6.90% implicit the past 52 weeks. Edwards Lifesciences Corporation (NYSE:EW) has a marketplace capitalization of $46.04 billion.

Artisan Mid Cap Fund stated the pursuing regarding Edwards Lifesciences Corporation (NYSE:EW) successful its Q1 2026 capitalist letter:

"We besides added to Edwards Lifesciences Corporation (NYSE:EW), Waters and Arthur J. Gallagher during the quarter. Edwards Lifesciences designs, develops, manufactures and markets products and services for the attraction of late-stage cardiovascular disease. The institution has a agelong past of enactment successful bosom valve replacement products and is the marketplace person successful minimally invasive valves delivered via catheters. We added to the presumption arsenic the halfway aortic valve franchise has been reaccelerating and request for newer tricuspid valves has been rapidly growing, expanding Edwards’ addressable market. This adjacent merchandise rhythm is supported by beardown objective information and expanding doc adoption, with Edwards gaining stock arsenic competing solutions person struggled to lucifer its objective outcomes. After respective years of dense concern to enactment semipermanent growth, we expect stronger gross maturation to thrust borderline expansion."

Read Entire Article